Securities Code: 300401 Bond Code: 123178 Securities Abbreviation: Huadian Biology Bond Abbreviation: Huadian Convertible Announcement No.: 2026-014
ZHEJIANG HUADIAN BIOLOGICAL PHARMACEUTICAL CO., LTD. Announcement on the 2025 Profit Distribution Plan
The Company and all members of the Board of Directors guarantee the content of the information disclosure is true, accurate, and complete, and there are no false records, misleading statements, or major omissions.
I. Deliberation Procedures
Zhejiang Huadian Biological Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") held the seventh session of the Independent Directors' Special Meeting and the fifteenth meeting of the Seventh Board of Directors on April 16, 2026, and deliberated and approved the "Proposal on the 2025 Profit Distribution Plan."
1. Deliberation by the Independent Directors' Special Meeting
The seventh session of the Independent Directors' Special Meeting deliberated on this proposal. The independent directors believed that the Company's 2025 profit distribution plan complies with relevant laws and regulations and the "Articles of Association," aligns with the Company's overall development strategy, is conducive to the Company's sustained and stable healthy development, and does not harm the interests of the Company and all shareholders, especially small and medium shareholders. The independent directors agreed to submit this proposal to the Board of Directors for deliberation.
2. Deliberation by the Board of Directors
On April 16, 2026, the fifteenth meeting of the Seventh Board of Directors of the Company deliberated and approved the "Proposal on the 2025 Profit Distribution Plan." The Board of Directors agreed to submit this proposal to the Company's 2025 Annual General Meeting for deliberation.
This proposal still needs to be submitted to the Company's 2025 Annual General Meeting for deliberation.